Literature DB >> 21976808

Emergence of Vibrio cholerae Serotype Hikojima in Northern Tamil Nadu.

C Chandralekha1, Gowri Veligandla, R Vanaja.   

Abstract

Entities:  

Year:  2011        PMID: 21976808      PMCID: PMC3180948          DOI: 10.4103/0970-0218.84142

Source DB:  PubMed          Journal:  Indian J Community Med        ISSN: 0970-0218


× No keyword cloud information.
Sir, In 2009, a total of 155 stool samples were collected from patients suffering from cholera like illness. 13 isolates of Vibrio cholerae were obtained. They were identified, biotyped and serotyped by standard procedures. All the 13 Vibrio cholerae O1 isolates were of El Tor biotype, and serotype Hikojima. No other serotypes were found in this study. The serotype Hikojima is known to be very unstable, and has been demonstrated to interconvert and undergo serotype switching.(1) So the study reflects the importance of close monitoring and surveillance of the prevalent serotype. Out of the 13 isolates first case was reported in Feb 2009. Maximum of 4 cases were reported in August 2009. Among the 13 isolates most of the patients were from Vellore and the rest from neighbouring towns. Males (61.53%) were more affected than females (38.45%). All the cholera cases were in the pediatric age group (1 to 10 years). More cases were seen in the age group less than 2 years (38.46%). This was similar to previous studies from other parts of the country which showed that the infection rate of cholera is increasingly reported in children.(2) The antibiogram [Table 1] of 13 isolates showed 100% resistance to cotrimoxazole and nalidixic acid. However the sensitivity to ampicillin was variable, 46% isolates were highly sensitive, 31% showed moderate sensitivity and 23% showed resistance to ampicillin. This correlated with earlier studies(34) that reported resistance of Vibrio cholerae isolates to ampicillin, cotrimoxazole and nalidixic acid.
Table 1

Sensitivity pattern of Vibrio cholerae isolates n=13

Sensitivity pattern of Vibrio cholerae isolates n=13 Although ciprofloxacin resistance has been reported in India(34) in case of Vibrio cholerae O1 El Tor Ogawa, Hikojima strains isolated at our place were found to be 100% sensitive to ciprofloxacin in accordance with study by Neelam Taneja et al.(5) All the 13 isolates were sensitive (100%) to azithromycin. Previously ciprofloxacin, doxycyclin and tetracyclin were used as first line drugs in treatment of cholera. These drugs are not used in children due to their side effects. In present study only children were affected so azithromycin which showed 100% sensitivity could be used effectively and safely as the drug of choice in children to treat cholera.(67)
  7 in total

1.  Incidence of Vibrio cholerae in different age groups and sex in Aurangabad Province isolated during January 1994 to December 1994.

Authors:  P Slathia; M P Bansal
Journal:  Indian J Med Sci       Date:  1999-08

2.  Emergence of Vibrio cholerae O1 Biotype El Tor serotype Inaba in north India.

Authors:  Neelam Taneja; Manisha Biswal; Bansidhar Tarai; Meera Sharma
Journal:  Jpn J Infect Dis       Date:  2005-08       Impact factor: 1.362

3.  Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial.

Authors:  Wasif A Khan; Debasish Saha; Anisur Rahman; Mohammed A Salam; Joseph Bogaerts; Michael L Bennish
Journal:  Lancet       Date:  2002-11-30       Impact factor: 79.321

4.  Emergence of fluoroquinolone resistance in strains of Vibrio cholerae isolated from hospitalized patients with acute diarrhea in Calcutta, India.

Authors:  A K Mukhopadhyay; I Basu; S K Bhattacharya; M K Bhattacharya; G B Nair
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

5.  Azithromycin in the treatment of cholera in children.

Authors:  M K Bhattacharya; D Dutta; T Ramamurthy; D Sarkar; A Singharoy; S K Bhattacharya
Journal:  Acta Paediatr       Date:  2003-06       Impact factor: 2.299

6.  Serotype conversion in Vibrio cholerae O1.

Authors:  U H Stroeher; L E Karageorgos; R Morona; P A Manning
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

7.  Epidemiology & antibiograms of Vibrio cholerae isolates from a tertiary care hospital in Chandigarh, north India.

Authors:  Jagdish Chander; Neelam Kaistha; Varsha Gupta; Manjula Mehta; Nidhi Singla; Antariksh Deep; B L Sarkar
Journal:  Indian J Med Res       Date:  2009-05       Impact factor: 2.375

  7 in total
  2 in total

1.  Dissecting serotype-specific contributions to live oral cholera vaccine efficacy.

Authors:  Brandon Sit; Bolutife Fakoya; Ting Zhang; Gabriel Billings; Matthew K Waldor
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-16       Impact factor: 11.205

2.  Immunogenicity and waning immunity from the oral cholera vaccine (Shanchol™) in adults residing in Lukanga Swamps of Zambia.

Authors:  Harriet Ng Ombe; Michelo Simuyandi; John Mwaba; Charlie Chaluma Luchen; Peter Alabi; Obvious Nchimunya Chilyabanyama; Cynthia Mubanga; Luiza Miyanda Hatyoka; Mutinta Muchimba; Samuel Bosomprah; Roma Chilengi; Geoffrey Kwenda; Caroline Cleopatra Chisenga
Journal:  PLoS One       Date:  2022-01-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.